Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dalrada Technology Group ( (DHTI) ) has provided an update.
On January 21, 2026, Genefic Inc., a wholly owned subsidiary of Dalrada Technology Group, entered into a Master Performance Standby Letter of Credit and Guaranty Agreement, dated December 31, 2025, with IBS Equity Fund III, LLC, alongside a related Credit, Security, and Account Purchase Agreement, establishing up to $20 million in financial guarantees and up to $5 million in receivables-based revolving credit to support Genefic’s healthcare operations through December 31, 2030. The facilities are secured by first-priority liens on substantially all assets of both Genefic and Dalrada, including a pledge of 100% of Dalrada’s equity in its subsidiaries, and are further backed by an unlimited personal guaranty from Chairman and CEO Brian Bonar, a structure the board acknowledges creates significant conflicts of interest and effectively subordinates parent-company assets to Genefic’s obligations, increasing financial risk but providing critical liquidity and guarantee capacity for its specialty pharmacy and related services.
Spark’s Take on DHTI Stock
According to Spark, TipRanks’ AI Analyst, DHTI is a Neutral.
Dalrada Financial’s overall performance is hindered by significant financial challenges, including negative earnings and high leverage. While there are some positive short-term technical indicators, the overbought conditions suggest potential volatility. The valuation remains unattractive, primarily due to negative profitability metrics.
To see Spark’s full report on DHTI stock, click here.
More about Dalrada Technology Group
Dalrada Technology Group operates through subsidiaries including Genefic Inc., which provides healthcare services such as specialty pharmacy and related activities. The company’s business spans multiple segments, and it has pledged 100% of its equity interests in all direct and indirect subsidiaries, reflecting a consolidated, multi-segment operating structure supporting Genefic’s healthcare-focused growth.
Average Trading Volume: 55,452
Technical Sentiment Signal: Sell
Current Market Cap: $6.01M
For a thorough assessment of DHTI stock, go to TipRanks’ Stock Analysis page.